Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017

被引：14
|
作者：
Shimbashi, Reiko [1 ,2 ]
Suzuki, Motoi [1 ,2 ]
Chang, Bin [1 ]
Watanabe, Hiroshi [3 ]
Tanabe, Yoshinari [4 ]
Kuronuma, Koji [5 ]
Oshima, Kengo [2 ]
Maruyama, Takaya [6 ]
Takeda, Hiroaki [7 ]
Kasahara, Kei [8 ]
Fujita, Jiro [9 ]
Nishi, Junichiro [10 ]
Kubota, Tetsuya [11 ]
Tanaka-Taya, Keiko [1 ]
Matsui, Tamano [1 ]
Sunagawa, Tomimasa [1 ]
Oishi, Kazunori [1 ,12 ]
机构：
[1] Natl Inst Infect Dis, Tokyo, Japan
[2] Tohoku Univ, Grad Sch Med, Sendai, Miyagi, Japan
[3] Kurume Univ, Sch Med, Fukuoka, Japan
[4] Niigata Prefectural Shibata Hosp, Niigata, Japan
[5] Sapporo Med Univ, Sch Med, Sapporo, Hokkaido, Japan
[6] Natl Hosp Org Mie Natl Hosp, Tsu, Mie, Japan
[7] Yamagata Saisei Hosp, Yamagata, Japan
[8] Nara Med Univ, Nara, Japan
[9] Univ Ryukyus, Grad Sch Med, Nishihara, Okinawa, Japan
[10] Kagoshima Univ, Grad Sch Med & Dent Sci, Kagoshima, Japan
[11] Kochi Univ, Kochi Med Sch, Kochi, Japan
[12] Toyama Inst Hlth, Toyama, Japan
来源：
EMERGING INFECTIOUS DISEASES | 2020年 / 26卷 / 10期
关键词：
PNEUMONIAE SEROTYPE 12F; CONJUGATE VACCINE; POPULATION; IMPACT; OLDER; SPAIN;
D O I：
10.3201/eid2610.191531
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The decline in the proportion of pneumococcal conjugate vaccine (PCV)-covered serotypes among adult invasive pneumococcal disease (IPD) patients might change the overall effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) because its effectiveness differs according to serotype. Using the indirect cohort method, we calculated the effectiveness of PPSV23 against IPD among adults in Japan to assess the impact of the national pediatric PCV program. Clinical and epidemiologic information and pneumococcal isolates were collected from IPD patients >= 20 years of age through enhanced IPD surveillance during April 2013-December 2017. Adjusted effectiveness against PPSV23-serotype IPD was 42.2%. Despite a substantial decline in the proportion of 13-valent PCV serotypes during the study period (45% to 31%), the change in effectiveness for PPSV23-serotype IPD was limited (47.1% to 39.3%) and only marginal in the elderly population (39.9% to 39.4%). The pediatric PCV program had limited impact on PPSV23 effectiveness against IPD in adults.
引用
收藏
页码：2378 / 2386
页数：9
相关论文
共 50 条
  • [41] IMMUNOGENICITY AND SAFETY OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN PATIENTS WITH SPONDYLOARTHRITIS
    Muravyeva, N.
    Belov, B.
    Baranova, M.
    Cherkasova, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 854 - 855
  • [42] Pneumococcal Nasopharyngeal Carriage following Reduced Doses of a 7-Valent Pneumococcal Conjugate Vaccine and a 23-Valent Pneumococcal Polysaccharide Vaccine Booster
    Russell, F. M.
    Carapetis, J. R.
    Satzke, C.
    Tikoduadua, L.
    Waqatakirewa, L.
    Chandra, R.
    Seduadua, A.
    Oftadeh, S.
    Cheung, Y. B.
    Gilbert, G. L.
    Mulholland, E. K.
    CLINICAL AND VACCINE IMMUNOLOGY, 2010, 17 (12) : 1970 - 1976
  • [43] Baseline Pneumococcal IgG Levels and Response to 23-Valent Pneumococcal Polysaccharide Vaccine among Adults from Beijing, China
    Zhou, Shanshan
    Lv, Min
    Bai, Shuang
    Chen, Weixin
    Zhao, Wei
    Wang, Jian
    Zhang, Ao
    Li, Jing
    Xie, Hui
    Gao, Yanqing
    Li, Dongmei
    Wu, Jiang
    VACCINES, 2023, 11 (12)
  • [44] Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review
    Cornelius Remschmidt
    Thomas Harder
    Ole Wichmann
    Christian Bogdan
    Gerhard Falkenhorst
    BMC Infectious Diseases, 16
  • [45] A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
    Ngamprasertchai, Thundon
    Kositamongkol, Chayanis
    Lawpoolsri, Saranath
    Rattanaumpawan, Pinyo
    Luvira, Viravarn
    Chongtrakool, Piriyaporn
    Kaewkungwal, Jaranit
    Chokephaibulkit, Kulkanya
    Phisalprapa, Pochamana
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [46] Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review
    Remschmidt, Cornelius
    Harder, Thomas
    Wichmann, Ole
    Bogdan, Christian
    Falkenhorst, Gerhard
    BMC INFECTIOUS DISEASES, 2016, 16
  • [47] Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients
    Breiman, RF
    Keller, DW
    Phelan, MA
    Sniadack, DH
    Stephens, DS
    Rimland, D
    Farley, MM
    Schuchat, A
    Reingold, AL
    ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (17) : 2633 - 2638
  • [48] Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China
    Mo, Xiuting
    Tobe, Ruoyan Gai
    Liu, Xiaoyan
    Mori, Rintaro
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (11) : E353 - E361
  • [49] Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age
    Greenberg, Richard N.
    Gurtman, Alejandra
    Frenck, Robert W.
    Strout, Cynthia
    Jansen, Kathrin U.
    Trammel, James
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    VACCINE, 2014, 32 (20) : 2364 - 2374
  • [50] Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
    Schmoele-Thoma, Beate
    van Cleeff, Martin
    Greenberg, Richard N.
    Gurtman, Alejandra
    Jones, Thomas R.
    Sundaraiyer, Vani
    Gruber, William C.
    Scott, Daniel A.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 575 - 583
12345